Successful preemptive therapy with single‐dose rituximab for Epstein‐Barr virus infection to prevent post‐transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation

Abstract

In conclusion, preemptive therapy containing rituximab is expected to reduce the incidence of PTLD after HSCT and improve post-transplantation outcomes in children.